LeonaBio Names Mark F. Kubik Chief Business Officer To Lead Licensing, Partnerships And Corporate Development As Company Pushes Phase 3 Lasofoxifene For Metastatic Breast Cancer Forward

LeonaBio, Inc., a clinical-stage biopharmaceutical company focused on developing innovative treatments for diseases with significant unmet medical needs, announced the appointment of Mark F. Kubik as its Chief Business Officer. In this position, Kubik will oversee the company’s business development efforts, including licensing, partnership strategy, and broader corporate development initiatives.

Kubik is already familiar with LeonaBio, having previously served as a strategic consultant to the company. During that time, he played a key role in the major transaction announced in December 2025, in which LeonaBio secured the rights to the Phase 3 lasofoxifene development program. This program is aimed at treating metastatic breast cancer, a serious and difficult-to-treat condition with limited therapeutic options.

According to Mark Litton, Ph.D., President and Chief Executive Officer of LeonaBio, Kubik’s appointment arrives at an important stage for the company. Litton highlighted Kubik’s extensive operational experience, his strong global network, and his track record of executing high-impact strategic deals. With more than 25 years of experience, Kubik has established himself as a leader with a rare blend of strategic insight, deal-making expertise, and scientific understanding qualities that will be invaluable as LeonaBio advances lasofoxifene through Phase 3 development and continues to expand its oncology and neurodegeneration pipeline. Litton noted that the company looks forward to Kubik’s contribution in shaping the next chapter of LeonaBio’s growth.

Kubik expressed his enthusiasm about joining LeonaBio during what he described as a defining moment for the organization. He emphasized the importance and urgency of advancing lasofoxifene, a late-stage therapeutic candidate that holds significant potential to improve outcomes for patients with treatment-resistant metastatic breast cancer. 

Kubik also highlighted LeonaBio’s strong scientific foundation and its focused approach to addressing critical medical needs, noting that these strengths create a strong platform for future expansion. He added that he is eager to work with the team to broaden the company’s portfolio, pursue strategic collaborations, and help drive LeonaBio’s mission to deliver meaningful new treatment options for patients.